Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation in treating patients who have recurrent or refractory AIDS-related lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AIDS Malignancy Consortium
• Collaborator: National Cancer Institute (NCI)
• Treatments: Busulfan; Cyclophosphamide

Criteria

DISEASE CHARACTERISTICS:

• Intermediate- or high-grade non-Hodgkin's lymphoma or Hodgkin's disease

• Failed to achieve complete remission with initial therapy OR

• Relapsed after initial therapy

• May be in complete remission after salvage therapy

• Sensitive to most recent chemotherapy

• Improvement of at least 25% in bidimensional tumor measurements OR

• Improvement in evaluable disease sustained over 4 weeks

• Measurable or evaluable disease

• HIV-1 positive

• CD4 greater than 50 cells/mm^3 (unless not receiving optimal antiretroviral therapy)

• HIV RNA less than 110,000 copies/mL (unless not receiving optimal antiretroviral therapy)

• No active leptomeningeal or parenchymal CNS involvement NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age:

• Physiologic 18 and over

Performance status:

• Karnofsky 70-100%

Life expectancy:

• Not specified

Hematopoietic:

• Absolute neutrophil count greater than 1,000/mm^3

Hepatic:

• AST no greater than 3 times upper limit of normal

• Bilirubin no greater than 2.0 mg/dL (unless receiving indinavir)

Renal:

• Creatinine no greater than 2.0 mg/dL

Cardiovascular:

• No history of cardiac disease

• LVEF at least 45%

Pulmonary:

• No history of symptomatic pulmonary disease

• DLCO at least 60%

Other:

• No active opportunistic infections

• No cytomegalovirus retinitis or pneumonitis requiring maintenance therapy

• No sensitivity to E. coli-derived products

• Not pregnant

• Negative pregnancy test

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics

• At least 1 week since prior chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

Other:

• Chronic suppressive therapy for infection allowed